Product
TCA IR
Aliases
Kenacort-A 40, Kenalog®-40, Kenalog®-40 Injection, TCA IR 40 (2 other aliases)
6 clinical trials
3 indications
Indication
Osteoarthritis of the KneeIndication
Type 2 Diabetes MellitusClinical trial
An Open-label, Single Administration Study to Characterize the Local Duration of Exposure of Triamcinolone Acetonide From FX006 in Patients With Osteoarthritis (OA) of the KneeStatus: Completed, Estimated PCD: 2014-04-01
Clinical trial
An Open-label, Single Administration Study to Characterize the Systemic Pharmacokinetics and Local Extent and Duration of Exposure of Triamcinolone Acetonide From FX006 in Patients With Osteoarthritis of the KneeStatus: Completed, Estimated PCD: 2016-09-01
Clinical trial
A Double-Blind, Randomized, Parallel Group, Proof of Concept Study Comparing FX006 to Kenalog®-40 in Patients With Post-Traumatic Osteoarthritis of the KneeStatus: Terminated, Estimated PCD: 2016-07-01
Clinical trial
A Double-Blind, Randomized, Parallel Group, Dose-Ranging Study Comparing FX006 to Commercially Available Triamcinolone Acetonide Injectable Suspension in Patients With Osteoarthritis of the KneeStatus: Completed, Estimated PCD: 2013-04-01
Clinical trial
A Double-Blind, Randomized, Parallel Group Comparison of the Effects of FX006 and TCA IR (Triamcinolone Acetonide Suspension) on Blood Glucose in Patients With Osteoarthritis of the Knee and Type 2 Diabetes MellitusStatus: Completed, Estimated PCD: 2016-10-01
Clinical trial
A Double-Blind, Randomized, Single-Dose Study to Assess the Safety and Efficacy of FX006 for the Treatment of Pain in Patients With Osteoarthritis of the KneeStatus: Completed, Estimated PCD: 2016-01-01